Current applications of CD40-directed cancer immunotherapy rely on the release of endogenous tumor antigen for T cell priming and activation. Here the authors develop a bispecific CD40 agonistic antibody for modular delivery of antigenic peptides combined with CD40 stimulation and find that this improves T cell expansion and anti-tumor response in mice.’
- Aman Mebrahtu
- Ida Laurén
- Sara Mangsbo
